Brain Research

This article was originally published in a journal published by Elsevier, and the attached copy is provided by Elsevier for the author's benefit and for the benefit of the author's institution, for non-commercial research and educational use including without limitation use in instruction at your institution, sending it to specific colleagues that you know, and providing a copy to your institution's administrator.

All other uses, reproduction and distribution, including without limitation commercial reprints, selling or licensing copies or access, or posting on open internet sites, your personal or institution’s website or repository, are prohibited. For exceptions, permission may be sought for such use through Elsevier’s permissions site at:

http://www.elsevier.com/locate/permissionusematerial
Research Report

Dietary supplementation with uridine-5′-monophosphate (UMP), a membrane phosphatide precursor, increases acetylcholine level and release in striatum of aged rat

Lei Wanga, Meredith A. Albrechta,b, Richard J. Wurtmana,⁎

a Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, USA
b Department of Anesthesia and Critical Care, Massachusetts General Hospital, Boston, MA, USA

ARTICLE INFO

Article history:
Accepted 16 November 2006
Available online 19 December 2006

Keywords:
Acetylcholine
Microdialysis
Uridine
Phosphatidylcholine
CDP-choline
Aged rat

ABSTRACT

The biosynthesis of brain membrane phosphatides, e.g., phosphatidylcholine (PtdCho), may utilize three circulating compounds: choline, uridine (a precursor for UTP, CTP, and CDP-choline), and a PUFA (e.g., docosahexaenoic acid); moreover, oral administration of the uridine source uridine-5′-monophosphate (UMP) can significantly increase levels of the phosphatides throughout the rodent brain. Since PtdCho can provide choline for acetylcholine (ACh) synthesis, we determined whether UMP administration also affects ACh levels in striatum and striatal extracellular fluid, in aged and young rats. Among aged animals consuming a UMP-containing diet (2.5%, w/w) for 1 or 6 weeks, baseline ACh levels in striatal dialysates rose from 73 fmol/min to 148 or 197 fmol/min (P < 0.05). Consuming a lower dose (0.5%) for 1 week produced a smaller but still significant increase (from 75 to 92 fmol/min, P < 0.05), and elevated striatal ACh content (by 16%; P < 0.05). Dietary UMP (0.5%, 1 week) also amplified the increase in ACh caused by giving atropine (10 μM in the aCSF); atropine alone increased ACh concentrations from 81 to 386 fmol/min in control rats and from 137 to 680 fmol/min in those consuming UMP (P < 0.05). Young rats eating the UMP-containing diet exhibited similar increases in basal ECF ACh (from 105 to 118 fmol/min) and in the increase produced by atropine (from 489 to 560 fmol/min; P < 0.05). These data suggest that giving a uridine source may enhance some cholinergic functions, perhaps by increasing brain phosphatide levels.

© 2006 Elsevier B.V. All rights reserved.

Keywords:
Acetylcholine
Microdialysis
Uridine
Phosphatidylcholine
CDP-choline
Aged rat

1. Introduction

Phosphatidylcholine (PtdCho), the most abundant phosphatide, is the primary component of neuronal cell membranes. Brain PtdCho synthesis can be enhanced by its three circulating precursors (Kennedy and Weiss, 1956): choline, a pyrimidine nucleoside like uridine or cytidine, and a polyunsaturated fatty acid (PUFA) like docosahexaenoic acid (DHA) (Araki and Wurtman, 1998; Rapoport, 2001; Marszalek and Lodish, 2005); all three readily cross the blood–brain barrier (Li et al., 2001; Spector, 2001). Brain uridine can be phosphorylated by uridine kinase (Suzuki et al., 2004) to form uridine-5′-triphosphate UMP, uridine-5′-monophosphate; ACh, acetylcholine; PtdCho, phosphatidylcholine; PUFA, polyunsaturated fatty acid; CDP-choline, cytidine-5′-diphosphocholine; UTP, uridine-5′-triphosphate; CTP, cytidine-5′-triphosphate; DA, dopamine; DAG, diacylglycerol; HPLC–ECD, high-pressure liquid chromatography with electrochemical detection

0006-8993/$ – see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.brainres.2006.11.048
(UTP), which can be aminated (by CTP synthetase) to cytidine-5′-triphosphate (CTP) (Genchev and Mandel, 1974). CTP subsequently forms cytidine-5′-diphosphocholine (CDP-choline) – PtdCho’s immediate precursor – which combines with diacylglycerol (DAG) molecules, including those containing PUFA, to produce PtdCho (Weiss, 1995).

Giving rodents like Mongolian gerbils a single dose of the uridine source uridine-5′-monophosphate (UMP) by gavage, increases their brain levels of CDP-choline by 50% (Cansev et al., 2005); chronic consumption of UMP via the diet (0.5%, with or without gavaged DHA) increases by 13–48% brain levels of PtdCho and other phosphatides including phosphatidylethanolamine (PtdEtn), phosphatidylserine (PtdSer), and phosphatidylinositol (PtdIns) (Wurtman et al., 2006). Daily administration of UMP and DHA for 2 weeks also increases dendritic spine densities in the CA1 region of adult gerbil hippocampus (Sakamoto and Wurtman, 2006) and, after 3–4 weeks, the levels of synaptic proteins including synapsin-I and PSD-95 (Wurtman et al., 2006).

In vitro, uridine was shown to amplify the membrane phosphodiester formation and neurite outgrowth elicited by nerve growth factor (NGF) in rat pheochromocytoma (PC-12) cells. The effect involved both CTP-enhanced phosphatide synthesis (Richardson et al., 2003) and UTP activation of P2Y receptors (Pooler et al., 2005) inasmuch as it could be blocked by the antagonists suramin or Reactive Blue 2. In vivo, UMP consumption was shown to enhance striatal dopamine (DA) levels and release (Wang et al., 2005).

Since membrane PtdCho is known to be a source of choline for acetylcholine (ACh) synthesis (Ulus et al., 1989), we explored the effects of uridine consumption on brain ACh-mediated neurotransmission, using in vivo microdialysis.

2. Results

2.1. Effects of UMP dietary supplementation on baseline extracellular ACh levels in aged rat striatum

Since we previously showed that dietary consumption of UMP (2.5%) for 6 weeks can enhance brain choline transmission in aged rats (Wang et al., 2005), we initially fed aged rats this diet to evaluate UMP’s effects on extracellular ACh levels in rat striatum. Animals consumed the diet for 1 or 6 weeks, then dialysates were collected and assayed for ACh measurement, as described in Experimental procedures. Microdialysis was repeated in each rat on 2 consecutive days, adding 0.5 μM neostigmine to the aCSF on 1 day and 1.0 μM on the other. Two-way ANOVA with repeated measures revealed significant effects of UMP treatment (F(2,69) = 9.69, P < 0.01) and of neostigmine (F(1,68) = 54.86, P < 0.01) on increasing baseline extracellular ACh levels (Fig. 1A). Dietary pretreatment with UMP was the between-subjects factor, and neostigmine was the within-subjects factor; data from animals receiving just the control diet for different times did not differ, and were pooled. When rats were perfused with aCSF containing 1.0 μM neostigmine, baseline ACh concentrations in the dialysates were increased from 73 ± 11 fmol/min in control rats to 148 ± 14 and 197 ± 35 fmol/min in UMP-pretreated rats (after 1 and 6 weeks of treatment, respectively; Fig. 1A). Using aCSF containing 0.5 μM neostigmine, baseline ACh concentrations increased from 48 ± 7 fmol/min in control rats to 70 ± 6 and 97 ± 13 fmol/min in UMP-pretreated rats (after 1 and 6 weeks of treatment, respectively; Fig. 1A).

We further confirmed UMP’s effect on baseline extracellular ACh level, using aged rats receiving a lower dose of UMP (0.5%; Fig. 1B) for 1 week. This dose was chosen because it significantly increases brain PtdCho levels in gerbils (Wurtman et al., 2006). Baseline ACh concentrations in the dialysates increased from 75 ± 4 fmol/min in control rats to 92 ± 2 fmol/min in rats consuming UMP (with 1.0 μM neostigmine; P < 0.05; Fig. 1B).

2.2. Effects of UMP dietary supplementation on ACh tissue content in aged rat striatum

Striatal ACh tissue content was measured using a near-freezing procedure, among aged rats receiving either control...
or 0.5% UMP-containing diets for 1 week (but no neostigmine). Tissue collection and ACh extraction are described in detail in Experimental procedures. ACh contents in the control rats were 144±5 pmol/mg protein. UMP pretreatment significantly increased these values by 16% (P<0.05) (Fig. 2).

2.3. Effects of UMP dietary supplementation on ACh release enhanced by atropine in aged rats

Two-way ANOVA with repeated measures revealed significant effects of UMP both on basal ACh release and on ACh release after atropine administration (10 μM the aCSF, with 1 μM neostigmine), in striatum of aged rats (Fig. 3; F(1,33)=14.23, P<0.01). Among rats that had consumed the 0.5% UMP-containing diet for 1 week, baseline ACh concentrations rose from 81±6 fmol/min to 137±12 fmol/min. Atropine significantly (P<0.01) elevated ACh release, to a maximum of 386±47 fmol/min in control rats, and to 680±90 fmol/min in UMP-pretreated rats.

2.4. Effects of UMP dietary supplementation on ACh release enhanced by atropine in young rats

We also examined uridine’s effect in young (3 months old) rats. Rats were pretreated as the aged ones and ACh release was enhanced by atropine. Young rats eating the UMP-containing diet exhibited an increase in basal ECF ACh (from 105±10 to 118±10 fmol/min; P=0.18). UMP significantly amplified atropine-enhanced ACh release: in UMP-pretreated rats, average releases were 560±21 fmol/min, compared with 489±31 fmol/min in control rats (n=7 in each group; P<0.05).

To rule out the possibility that the increased ACh release was related to inhibition of acetylcholinesterase (AChE), the activities of this enzyme in striatum and hippocampus of young rats not undergoing dialysis were determined by a colorimetric method using acetylthiocholine substrate as described by Ellman et al. (1961). Activities of AChE were unchanged by UMP pretreatments in the striatum (150±6 vs. 159±5 nmol/min/mg of tissue, control vs. UMP; P>0.05) or hippocampus (9.0±0.3 vs. 9.1±0.5 nmol/min/mg of tissue, control vs. UMP; P>0.05).

2.5. Effects of UMP-containing diet on striatal phosphatide contents

To confirm that the UMP was increasing brain phosphatides in these animals, we measured PtdCho, PtdEtn, and PtdSer in striata of young rats consuming control or UMP diets for 6 weeks (n=6). These were 183±10, 197±13 and 44±5 nmol/mg protein, respectively, in control rats. They were increased significantly by 17%, 27%, and 30%, respectively, in animals consuming the UMP diet (all P<0.05, unpaired t-test; Fig. 4). Synaptic levels of total phosphatides also increased significantly, from 424±26 to 521±24 nmol/mg protein (P<0.05).

Fig. 2 – Effect of UMP on striatal ACh tissue content. ACh tissue content was measured among aged rats fed control or UMP-containing (0.5%) diets for 1 week (n=6). Bars indicate means±SEM. *P<0.05 vs. control (unpaired t-test).

Fig. 3 – Effect of UMP on atropine-enhanced ACh release in aged rat striatum. Atropine-enhanced (10 μM) ACh release was measured in aged rats fed either control or UMP-containing (0.5%) diets for 1 week. Data are given as means±SEM. *P<0.05 vs. corresponding control (two-way ANOVA with repeated measures and unpaired t-test). Baseline samples, collected 60 min prior to atropine administration, exhibited a significant increase in ACh levels, as did the initial two samples collected after atropine administration.

Fig. 4 – Effects of UMP on striatal phosphatide content. Phosphatide contents were measured in striata of 3-month-old young rats fed control or UMP-containing (2.5%) diets for 6 weeks. Bars indicate means±SEM. *P<0.05 vs. control (unpaired t-test).
3. Discussion

These data show that basal ACh release (Fig. 1A, B) and evoked ACh release caused by atropine (Fig. 3) are both increased in striata of rats fed a choline-containing diet enriched with UMP. Moreover, striatal ACh content (Fig. 2) is significantly increased with no effects on acetylcholinesterase activity, suggesting that synthesis of ACh is elevated. Since UMP increased both the levels and apparent release of striatal ACh, we hypothesize that its primary mechanism was to increase the availability of choline (e.g., from membrane PtdCho). It could, of course, also act on M2 receptors.

That the source of the additional choline is choline in membrane phosphatides, mainly PtdCho, is suggested by the increased synthesis (Cansev et al., 2005) and levels (Wurtman et al., 2006; and Fig. 4) of this phosphatide after chronic pretreatment with dietary UMP. Since brain levels of PtdCho are orders of magnitude greater than those of ACh, the 17% increase in PtdCho could readily provide sufficient choline for the observed increases in ACh.

The cellular loci of the increased membrane phosphatides probably include synaptic vesicles and synaptic membranes since, as we recently observed, brain levels of various pre- and post-synaptic proteins, including synapsin-I and PSD-95, are increased among animals consuming a UMP-containing diet (Wurtman et al., 2006). Thus, uridine consumption may produce more or larger synapses or synaptic vesicles which may also contribute to increasing striatal ACh content and release.

UMP pretreatment most likely affects membrane phosphatide production as well as neurite outgrowth in PC-12 cells (Pooler et al., 2005) and hippocampal dendritic spine formation in vivo (Sakamoto and Wurtman, 2006) by two mechanisms: by increasing CTP levels, it increases the formation of CDP-choline (Cansev et al., 2005); and by increasing brain UTP, it activates metabotropic P2Y receptors (Pooler et al., 2005). Oral UMP is rapidly absorbed, appearing in the circulation as uridine (Sonoda and Tatibana, 1978). Consumption of UMP (2000 mg) by humans raises plasma uridine levels by 3-fold (from 6.0 to 21.9 μM), for 5–6 h (Cansev, 2006). Circulating uridine crosses the blood–brain barrier via an adenosine transporter (the concentrative nucleoside transporter type 2; CNT2) (Li et al., 2001), which is unsaturated at physiologic plasma uridine concentrations (Cansev et al., 2005). Thus, dietary UMP can increase brain levels of uridine and subsequently, as shown in gerbils, brain levels of UTP, CTP and CDP-choline (Cansev et al., 2005).

Uridine also affects PtdCho synthesis and, possibly, ACh release via UTP-mediated activation of the P2Y receptor (Neary et al., 1996). A subset of the metabotropic P2Y (P2Y1, P2Y4, and P2Y6) receptors, once activated by UTP, increases intracellular levels of DAG and inositol triphosphate (IP3), and subsequently, calcium influx.

UMP consumption produces parallel increases in rat brain phosphatide levels within all regions examined, e.g. striatum, hippocampus, cortex, brain stem and cerebellum (Cansev et al., in preparation), probably reflecting the homogeneity, among regions, of the proteins that take up uridine into the brain (Cansev, 2006) and that catalyze the steps in the Kennedy cycle. Since the levels of ACh in striatal dialysates are much higher and more readily measured than those in hippocampal or cortical dialyses (Wu et al., 1988), and since the UMP-induced rise in brain phosphatides may mediate the increase in ACh, we collected ECF (dialysis) samples from striatum for these studies. Striatal neurons are involved in various types of learning in rats (e.g., stimulus–response habits as well as motor, perceptual, and cognitive skills) (Jog et al., 1999), and cholinergic interneurons modulate these neuronal circuits (Kaneko et al., 2000). Microdialysis studies have shown that when rats used response strategies rather than spatial strategies for learning, striatal ACh release increased (Chang and Gold, 2003). Moreover, selective ablation of striatal cholinergic neurons impairs procedural learning in mice (Kitabatake et al., 2003). Thus, the enhancement in striatal cholinergic neurotransmission, after oral UMP administration, that we observe (e.g. Figs. 1 and 3), may be associated with enhanced learning and memory in rodents.

Brain ACh-mediated neurotransmission is involved in cognitive processes in humans and other mammals (Drachman, 1977; Everitt and Robbins, 1997). The ability of oral UMP, with choline, to increase the levels of ACh and phosphatides in rats raises the possibility that this compound might also be useful in treating age-related memory dysfunction.

4. Experimental procedures

4.1. Animals

Young (3 months old) and aged (22 months old) male Fischer 344 rats were purchased from the National Institute on Aging (Harlan Sprague-Dawley, Indianapolis, IN). The younger animals were used to confirm the increase in brain phosphatides produced by uridine (Wurtman et al., 2006); the aged animals were used for measurement of ACh levels and release. The animals were reared in a socially restricted environment (i.e., individual housing and minimal handling), and exposed to a 12-h light/dark cycle with food and water provided ad libitum. All experimental procedures were approved by the Massachusetts Institute of Technology Committee on Animal Care.

Animals had been fed a standard control diet (Teklad Global 16% protein rodent diet, TD.00217, which contains 0.1% choline chloride; Harlan Teklad, Madison, WI), or this diet fortified with UMP.2Na· (0.5% UMP diet: TD.04226; 2.5% UMP diet: TD.03938; w/w) for 1 or 6 weeks prior to microdialysis experiments. Aged rats consumed an average of 10 g of food per day and there was no difference between consumption of the control and UMP-containing diets. Thus 2.5% of UMP provided approximately 500 mg/kg/day of UMP, or 330 mg/kg/day of free uridine (100 or 66 mg/kg/day, respectively, of the 0.5% diet), and 50 mg/kg/day of choline. These diets also contained no detectable nucleosides or nucleotides as analyzed by HPLC. When the rats were sacrificed after experiments, their stomach contents were examined; residual food was present in all of the animals indicating that uridine and choline were still being absorbed.
4.2. Surgery

Stereotaxic surgery was carried out 1 day prior to a microdialysis experiment, according to the method described in detail by Osborne et al. (1991), using a CMA/11 probe (OD 0.24 mm, 4 mm, 6000 Da, CMA, Sweden). The probe was permanently implanted into the right side of the striatum (AP = +0.5, ML = −3.0, DV = 7.3 mm), according to the atlas of Paxinos and Watson (2004), under ketamine and xylazine (80 and 10 mg/kg BW, i.p., respectively) anesthesia. Average recoveries of microdialysis probes were 12.0 ± 0.3% for ACh (n = 22). Data were not corrected for probe recoveries.

4.3. Microdialysis

Microdialysis was performed for 1 or 2 days on freely moving rats, kept in a circular bowl on a rotating platform, obviating the need for a liquid swivel. Artificial cerebrospinal fluid (aCSF), containing, in mM: NaCl, 121; NaHCO3, 25; KCl, 3.5; CaCl2, 1.2; MgCl2, 1.2; Na2HPO4, 1, was bubbled with 95% O2 and kept at 37 °C. Animals were sacrificed using a cryostat (Leica, CM 3000) at −18 °C. The atlas of Paxinos and Watson and the ink stains in the contralateral side were used to identify major landmarks and to confirm the coordinates.

Tissue ACh was extracted according to the method described in detail by Takahashi et al. (1997). The dissected striata were homogenized on ice (50 mg of tissue with 1 ml 100 mM HClO4, 50 μM EDTA). A 10 μl aliquot was used for total protein determination (bicinchoninic acid assay, Sigma). The homogenates were then centrifuged (14,000 rpm, 15 min, 4 °C) and filtered with Ultrafree-MC centrifugal filter units (Millipore; 14,000 rpm, 1 min, 4 °C). Tissue ACh values were normalized to the amount of protein per sample.

4.5. ACh assay

ACh assay was carried out using a BAS 200A HPLC system with electrochemical detection (HPLC-ECD; BAS, West Lafayette, IN), as described by Damsma and Westerink (1991). A BAS ACh/choline analytical column cartridge and post-column enzyme reactor (MF-6150 and MF-6151) were used at 37 °C to separate ACh and choline. The mobile phase (0.8 ml/min) consisted of 40 mM Na2HPO4, 0.5 mM Na2EDTA and 0.5 mM Kathon CG at pH 8.4. The compounds were measured using a modified working electrode (with horseradish peroxidase and a redox polymer on its surface) at a potential of +100 mV vs. Ag/AgCl. Samples were injected using an Alltech 580 autosampler, and data were collected and calculated using an AllChrom workstation (Alltech, Deerfield, IL).

4.6. Brain phosphatide assay

Striatal levels of the brain major phosphatides (PtdCho, PtdEtn, and PtdSer) were extracted according to the method of Folch et al. (1957), and measured as described previously (Lopez-Coviella et al., 1995). The corpus striatum was dissected, frozen in liquid nitrogen, sonicated in methanol, and mixed with 2 volumes of chloroform, then 2 volumes of 50% methanol/water. After centrifugation the organic phase (locus of the phosphatides) was dried under vacuum. The residue was reconstituted in chloroform/methanol (l: l), and an aliquot of the phosphatide extract was subsequently purified by TLC on silica gel G plates (Adsorbosil-Plus 1, Alltech), using a system consisting of chloroform/ethanol/triethylamine/water (30:34:30:8) as the mobile phase. Phosphatide standards were used to identify the corresponding bands under UV light after the plates were sprayed with 0.1% diphenylhexatriene in petroleum ether. The total amounts of each of the phosphatides were determined by phosphate assay (Svanborg and Svennerholm, 1961) and expressed per milligram of protein. Total protein levels were determined from methanol homogenates using the bicinchoninic acid assay.

4.7. Data analysis

Statistical analyses were carried out using SPSS 12.0. Data were represented as means ± SEM. Unpaired t-test, one-way ANOVA, Student–Newman–Keuls (SNK) test, one-way ANOVA with post hoc Dunnett’s test, and Chi-square tests were used. Statistical significance was set at p < 0.05.
ANOVA and two-way ANOVA with repeated measures were used to assess the statistical significance of effects. Tukey’s post hoc analyses were used when appropriate. The significance level was set at $P<0.05$.

Acknowledgments

The authors thank Carol Watkins, Maya Hasan, Ingrid Richardson, Mehmet Cansev and Luke Schmitt for advice and excellent assistance. UMP $2\text{Na}^+$ was kindly provided by Numico Research, Wageningen, The Netherlands. These studies were supported by grants from The National Institutes of Mental Health (Grant No. 2 R01 MH028783-30), and from The Center for Brain Sciences and Metabolism Charitable Trust.

REFERENCES


Sakamoto, T., Wurtman, R.J., 2006. Increased dendritic spine density in adult gerbil hippocampus following oral UMP and DHA supplementation. 10th International Conference on Alzheimer’s Disease and Related Disorders. Madrid, Spain.


increases acetylcholine release and protects against the stimulation-induced decrease in phosphatide levels within membranes of rat corpus striatum. Brain Res. 484, 217–227.


